[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565511":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":34,"studyPopulation":22,"armGroups":35,"interventions":53,"overallOfficials":67,"centralContacts":71,"locations":80,"responsibleParty":95,"collaborators":22,"id":97,"slug":22,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":22,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":22,"enrollmentInfo":105,"targetDuration":22,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":22,"overallStatus":83,"whyStopped":22,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"JW Pharmaceutical","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":22},[9,13],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in msSBP (Systolic Blood Pressure)","Check msSBP","week 8",{"measure":14,"description":15,"timeFrame":12},"Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)","Check LDL-C",[17,20],{"measure":18,"description":11,"timeFrame":19},"change from baseline in msSBP","week 4",{"measure":21,"description":15,"timeFrame":19},"Change and percent change from baseline in LDL-C",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":29},"QUADRUPLE",[30,31,32,33],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.",[36,42,48],{"label":37,"type":38,"description":39,"interventionNames":40},"JW0104+C2402","EXPERIMENTAL","JW0104+C2402, 8 weeks, QD (Quaque Die)",[41],"Drug: JW0104+C2402",{"label":43,"type":44,"description":45,"interventionNames":46},"JW0104+C2403","ACTIVE_COMPARATOR","JW0104+C2403, 8 weeks, QD",[47],"Drug: JW0104+C2403",{"label":49,"type":44,"description":50,"interventionNames":51},"C2402","C2402, 8 weeks, QD",[52],"Drug: C2402",[54,60,64],{"type":55,"name":37,"description":56,"armGroupLabels":57,"otherNames":58},"DRUG","For 8 weeks(PO (Per Oral), QD)",[37],[59],"NA (Not Applicable)",{"type":55,"name":43,"description":61,"armGroupLabels":62,"otherNames":63},"For 8 weeks(PO, QD)",[43],[59],{"type":55,"name":49,"description":61,"armGroupLabels":65,"otherNames":66},[49],[59],[68],{"name":69,"affiliation":5,"role":70},"Minjung Kim","STUDY_CHAIR",[72,76],{"name":69,"role":73,"phone":74,"phoneExt":22,"email":75},"CONTACT","+82-2-840-6861","kmj@jwhealthcare.com",{"name":77,"role":73,"phone":78,"phoneExt":22,"email":79},"Dongryung Lee","+82-2-840-6982","dongryung.lee@jwhealthcare.com",[81],{"facility":82,"status":83,"city":84,"state":22,"zip":85,"country":86,"countryCode":22,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"Gangdong Sacred Heart Hospital","RECRUITING","Seoul","05355","South Korea",{"type":88,"coordinates":89},"Point",[90,91],126.9784,37.566,{"lat":91,"lon":90},[94],{"name":69,"role":73,"phone":74,"phoneExt":22,"email":75},{"type":96,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100565511",false,"NCT06643130","Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia","A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia","Inclusion Criteria:\n\n* Patients with hypertension and dyslipidemia\n\nExclusion Criteria:\n\n* The subject not meet the specified msBP and LDL-C level","ALL","19 Years",{"count":106,"type":107},162,"ESTIMATED","INTERVENTIONAL",[110],"PHASE3","A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia",[113,114],"Hypertension","Dyslipidemia","2025-09-02",{"date":117,"type":118},"2025-09-09","ACTUAL",{"date":120,"type":118},"2024-12-02",{"date":122,"type":107},"2026-04",{"name":5,"class":6},1]